

# Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/N0EC287266C2EN.html>

Date: May 2022

Pages: 49

Price: US\$ 3,500.00 (Single User License)

ID: N0EC287266C2EN

## Abstracts

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 4 - Drugs In Development, 2022, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions. The molecules developed by companies in Phase III, Phase II and Phase I stages are 1, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas

Central Nervous System which include indications Smoking Cessation, Alcohol Addiction, Major Depressive Disorder and Psychiatric Disorders.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)

The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects

The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Overview

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Companies Involved in  
Therapeutics Development

Ctcbio Inc

Sobrerera Pharma AB

Sopharma AD

Suven Life Sciences Ltd

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Drug Profiles  
(varenicline tartrate + bupropion hydrochloride) SR - Drug Profile

Product Description

Mechanism Of Action

History of Events

CDFE-0318 - Drug Profile

Product Description

Mechanism Of Action

History of Events

cytisinicline - Drug Profile

Product Description

Mechanism Of Action

History of Events

ropanicant [INN] - Drug Profile

Product Description

Mechanism Of Action

## History of Events

Small Molecule to Antagonize CHRN2 and CHRNA4 for Psychiatric Disorders - Drug Profile

Product Description

Mechanism Of Action

varenicline tartrate - Drug Profile

Product Description

Mechanism Of Action

## History of Events

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Dormant Products

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Product Development

Milestones

## Featured News & Press Releases

Apr 27, 2022: Achieve Life Sciences announces successful, statistically significant smoking cessation results in phase 3 ORCA-2 clinical trial of cytisinicline in adult smokers

Jan 25, 2022: Achieve Life Sciences announces initiation of the phase 3 ORCA-3 clinical trial evaluating cytisinicline for smoking cessation

Jan 04, 2022: Achieve Life Sciences announces completion of last subject, last follow-up visit in phase 3 ORCA-2 trial of cytisinicline for smoking cessation

Dec 22, 2021: Achieve Life Sciences announces \$25 million loan facility from Silicon Valley Bank to fund cytisinicline smoking cessation clinical development

Nov 22, 2021: Achieve Life Sciences announces phase 3 ORCA-2 trial of cytisinicline in smoking cessation clears final review by Data Safety Monitoring Committee (DSMC)

Nov 02, 2021: Achieve Life Sciences announces FDA acceptance of IND application for Cytisinicline's second planned indication for nicotine E-cigarette cessation

Oct 14, 2021: Class 2 Medicines Recall: Pfizer Ltd, Champix (all strengths) film-coated tablets

Sep 20, 2021: Health Canada approves COVID-19 vaccine brand name Comirnaty

Sep 16, 2021: Pfizer expands voluntary nationwide recall to include all lots of CHANTIX (varenicline) tablets due to N-Nitroso Varenicline Content

Sep 14, 2021: Achieve Life Sciences announces presentation of Cytisinicline data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference

Aug 13, 2021: Pfizer expands voluntary nationwide recall to include four additional lots of CHANTIX (varenicline) tablets due to NNitroso Varenicline content

Aug 13, 2021: Achieve Life Sciences announces expansion of Cytisinicline clinical operations team and granting of inducement awards

Aug 11, 2021: Achieve announces two patents granted by USPTO for novel

Cytisinicline dosing and administration regimen

Aug 05, 2021: Therapeutic Goods Administration provides update on Varenicline

Jul 22, 2021: Achieve Life Sciences awarded grant from the National Institutes of Health (NIH) for the evaluation of cytisinicline in cessation of nicotine e-cigarette use

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Ctcbio Inc, 2022

Pipeline by Sobrera Pharma AB, 2022

Pipeline by Sopharma AD, 2022

Pipeline by Suven Life Sciences Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022



## I would like to order

Product name: Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/N0EC287266C2EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N0EC287266C2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970